Cancer immunotherapy utilizing immune-checkpoint inhibitors (ICI), such as, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), PD1 (programmed cell death protein 1), and PDL1 (ligand for PD1), have revolutionized the field of cancer treatment [1]. Here, CTLA4 is linked to cancer.